3rd Quarter - Report

NATIONAL VENTURE CAPITAL ASSOCIATION for NATIONAL VENTURE CAPITAL ASSOCIATION

Firm
Client
Income
—
Expenses
$551,024
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Banking BAN

Implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (PL 111-203) Implementation of the JOBS Act Review of decimalization study by the SEC, required under the JOBS Act

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN New —
MARK HEESEN —
KELLY SLONE —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; White House Office; Securities & Exchange Commission (SEC); Treasury, Dept of

Telecommunications TEC

HR 1468 Secure IT Act: Bills to protect critical infrastructure against cyber based espionage, IP theft and terror attacks; Privacy and Information Sharing issues; S.21 Cybersecurity and American Cyber Competitiveness Act of 2013; HR 624 Cyber Intelligence Sharing and Protection Act (CISPA)

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN New —
MARK HEESEN —
KELLY SLONE —

Contacted: White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Treasury, Dept of; Securities & Exchange Commission (SEC); SENATE

Bills named: H.R. 624 (113th), H.R. 1468 (113th), S. 21 (113th)

Health Issues HCR

No bill #: Lobbied Congress to work the FDA to create a new approval pathway that could help expediate the development of certain drugs that address unmet medical needs, referred to as a special medical use pathway which can be used for a broad set of discussions No bill #: Lobbied Congress on the need for a transparent regulatory pathway for market-based reimbursement for advanced diagnostics. FDA Medical Mobile Apps

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN New —
MARK HEESEN —
KELLY SLONE —

Contacted: Food & Drug Administration (FDA); White House Office; SENATE; Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES; Treasury, Dept of

Energy/Nuclear ENG

Cleantech and Energy Policy Issues. New Energy Innovation Tax issues; ARPA-E Funding; HR 2609 FY 2014 Energy and Water Appropriations.

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN New —
MARK HEESEN —
KELLY SLONE —

Contacted: Securities & Exchange Commission (SEC); Treasury, Dept of; HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); White House Office

Bills named: H.R. 2609 (113th)

Immigration IMM

Support for S.310, Startup Act 3.0; S.169 Immigration Innovation Act of 2013; S.189 Startup VISA Act of 2013; Gang of 8 Bipartisan Framework for Comprehensive Immigration Reform; Invest VISA, Entrepreneurial VISA, HR 2131 S744 Border Security, Economic Opportunity and Immigration Modernization Act

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN New —
MARK HEESEN —
KELLY SLONE —

Contacted: SENATE; Food & Drug Administration (FDA); White House Office; Treasury, Dept of; Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES

Bills named: S. 169 (113th), S. 189 (113th), H.R. 2131 (113th), S. 310 (113th)

Taxation/Internal Revenue Code TAX

S.232/HR 1295 Medical Device Access and Innovation Protection Act: would appeal the medical device tax as part of the ACA; S. Con Resolution 8: an original resolution setting forth the Congressional Budget for FY2014 which would repeal the medical device tax but not identify a pay for: HR 523 Protect the Medical Innovation Act of 2013

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN New —
MARK HEESEN —
KELLY SLONE —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA); Treasury, Dept of; Securities & Exchange Commission (SEC); SENATE

Bills named: H.R. 523 (113th), S. 232 (113th), H.R. 1295 (113th)

Copyright/Patent/Trademark CPT

Shield Act of 2013, HR 845 - provide new limits to Patent Infringement lawsuits brought by non-practicing entities. Monitored issues. Have not taken a position on the legislation. HR 2024-End Anonymous Patents Act, enhanced disclosure of real party interests; S. 866 Patent Reality Improvement Act, expansio of CBM program; S1013: Patent Abuse Reduction Act, disclosure of real party interest.

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN New —
MARK HEESEN —
KELLY SLONE —

Contacted: HOUSE OF REPRESENTATIVES; Treasury, Dept of; Securities & Exchange Commission (SEC); SENATE; White House Office; Food & Drug Administration (FDA)

Bills named: H.R. 2024 (113th), S. 866 (113th), H.R. 845 (113th)

Science/Technology SCI

Basic science research funding HR 2981 Technology and Research National Security and Future Economic Resiliency Act (TRANSFER Act)

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN New —
MARK HEESEN —
KELLY SLONE —

Contacted: HOUSE OF REPRESENTATIVES; Securities & Exchange Commission (SEC); Food & Drug Administration (FDA); White House Office; SENATE; Treasury, Dept of

Bills named: H.R. 2981 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.